

# CELYAD ONCOLOGY SA

ISIN: BE0974260896 WKN: - Asset Class: **Stock**

## Company

2024/07/16 17:35:12



Price

**0.27** EUR

Difference ▼ -0.37%(0.00)



## Contact Details

CELYAD ONCOLOGY SA  
- -  
Axis Business Park, Rue André  
Dumont 9  
1435 Mont-Saint-Guibert

Tel: +32-10-039-41-00  
Fax: +32-10-039-41-41  
Web: <http://www.celyad.com>  
E-mail: [info@celyad.com](mailto:info@celyad.com)

## Company Profile

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	11,121,000		14,825,000		34,292,000	
<b>Common stock capital</b>		32,949,000		78,585,000		78,585,000
<b>Fixed assets</b>	5,161,000		4,891,000		45,651,000	
<b>Equity capital of a company</b>		-10,327,000		-12,314,000		27,008,000
<b>Cash and cash equivalents</b>	7,004,000		12,445,000		30,018,000	
<b>Accrued liabilities</b>		1,000		13,000		53,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		2,932,000		10,426,000		13,827,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		23,677,000		21,604,000		39,108,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		6,143,000		4,842,000		20,694,000
<b>Total assets</b>	16,282,000	16,282,000	19,716,000	19,716,000	79,943,000	79,943,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	17	39	103
<b>Equity ratio</b>	-63.43%	-62.46%	33.78%
<b>Debt-equity ratio</b>	-257.66%	-260.11%	196.00%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	2.21%	0.96%	2.49%

# CELYAD ONCOLOGY SA

ISIN: BE0974260896 WKN: - Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	102,000	0	0
<b>Net income</b>	-8,448,000	-40,935,000	-26,512,000
<b>EBIT</b>	-8,587,000	-41,147,000	-26,961,000
<b>Operating income before taxes</b>	-8,639,000	-41,332,000	-27,189,000
<b>Cash Flow</b>	-15,202,000	-28,010,000	-26,643,000
<b>Net interest income</b>	-52,000	-185,000	-228,000
<b>Research and development expenses</b>	3,881,000	17,697,000	19,496,000
<b>Income taxes</b>	-191,000	-397,000	-677,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	6,000	0	0

## Board of Directors

Hilde Windels	Chairman of Supervisory Board
Marina Udier	Member of Supervisory Board
Ami Shah	Member of Supervisory Board
Andrea Gothing	Member of Supervisory Board
Dominic Piscitelli	Member of Supervisory Board
John LiPuma	Member of Supervisory Board
Jonathan James	Member of Supervisory Board
Sage Mandel	Member of Supervisory Board
Serge Goblet	Member of Supervisory Board

## Members of Management Board

Georges Rawadi	Chairman of Managing Board
An Phan	Member of Executive Committee
David Georges	Member of Executive Committee
Eytan Breman	Member of Executive Committee
Hannes Iserentant	Member of Executive Committee